Literature DB >> 19632726

Thyroid function and postpartum mood disturbances in Greek women.

Irene Lambrinoudaki1, Demetrios Rizos, Eleni Armeni, Paraskevi Pliatsika, Angeliki Leonardou, Angeliki Sygelou, John Argeitis, Georgia Spentzou, Dimitrios Hasiakos, Ioannis Zervas, Constantinos Papadias.   

Abstract

BACKGROUND: Postpartum mood disturbances are very common with postpartum blues being as high as 44.5% among Greek women. This study aimed to investigate whether thyroid function within the normal range affects the incidence of postpartum mood disturbances.
METHODS: In a cross-sectional study in the maternity ward of Aretaieion Hospital, 57 Greek women were evaluated for postpartum mood swings by the Maternity Blues Questionnaire and the Edinburgh Postnatal Depression Scale on the first and sixth week postpartum. Serum Free T4, Free T3 and TSH concentrations as well as thyroglobulin and thyroid peroxidase antibodies were measured on admission for delivery and daily until the fourth postpartum day. We examined the association between hormone and antibody levels, and scores in the two scales evaluating postpartum mood disturbances.
RESULTS: Prepartum serum FT3 and FT4 correlated negatively with blues scores in the first week postpartum (blues on day 4: with FT3, rho=-0.44, p < or = 0.01; with FT4 rho=-0.36, p < or = 0.01). Women with lower FT3 and FT4 levels belonged to the high scoring group (high scoring group: FT3=1.22 pg/ml, FT4=0.66 ng/dl; low scoring group: FT3=1.64 pg/ml, FT4=0.73 ng/dl). Serum FT3 showed a negative independent correlation with postpartum blues scores in the first postpartum days. No association was found between thyroid antibody levels and mood scores.
CONCLUSION: Our findings indicate an association between the occurrence of postpartum mood disorders and antenatal thyroid function. Within normal limits, lower levels of serum FT3 and FT4 are associated with increased incidence of mood disturbances in the first postpartum week. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632726     DOI: 10.1016/j.jad.2009.07.001

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Positive thyroid peroxidase antibody titer is associated with dysphoric moods during pregnancy and postpartum.

Authors:  Maureen W Groer; Jessica H Vaughan
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2012-11-20

2.  Late pregnancy thyroid-binding globulin predicts perinatal depression.

Authors:  Cort Pedersen; Jane Leserman; Nacire Garcia; Melissa Stansbury; Samantha Meltzer-Brody; Jacqueline Johnson
Journal:  Psychoneuroendocrinology       Date:  2015-12-18       Impact factor: 4.905

3.  Elevated Thyroid Peroxidase Antibody Increases Risk of Post-partum Depression by Decreasing Prefrontal Cortex BDNF and 5-HT Levels in Mice.

Authors:  Yingying Zhou; Xinyi Wang; Yuhang Zhao; Aihua Liu; Tong Zhao; Yuanyuan Zhang; Zhongyan Shan; Weiping Teng
Journal:  Front Cell Neurosci       Date:  2017-01-09       Impact factor: 5.505

4.  Postpartum Mood Disorders and Thyroid Autoimmunity.

Authors:  Maria Le Donne; Carmela Mento; Salvatore Settineri; Alessandro Antonelli; Salvatore Benvenga
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-04       Impact factor: 5.555

Review 5.  Postpartum depression in maternal thyroidal changes.

Authors:  Paula Michele da Silva Schmidt; Aline Longoni; Ricardo Tavares Pinheiro; Adriano Martimbianco de Assis
Journal:  Thyroid Res       Date:  2022-03-29

6.  Economic and Health Predictors of National Postpartum Depression Prevalence: A Systematic Review, Meta-analysis, and Meta-Regression of 291 Studies from 56 Countries.

Authors:  Jennifer Hahn-Holbrook; Taylor Cornwell-Hinrichs; Itzel Anaya
Journal:  Front Psychiatry       Date:  2018-02-01       Impact factor: 4.157

Review 7.  Review of the prevalence of postnatal depression across cultures.

Authors:  Siti Roshaidai Mohd Arifin; Helen Cheyne; Margaret Maxwell
Journal:  AIMS Public Health       Date:  2018-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.